China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s Laboratories Ltd. (BOM: 500124) for its HLX15, a biosimilar version of Johnson & Johnson’s Darzalex (daratumumab). Under the agreement, Dr. Reddy’s will obtain exclusive commercialization rights to the anti-CD38 monoclonal antibody (mAb), including both intravenous and subcutaneous formulations, in the United States and 42 other countries and regions in Europe.
Deal Terms and Financials
Henlius will be responsible for the development, manufacturing, and commercial supply of HLX15. The company may receive an upfront payment of USD 33 million and milestone payments, with the total potentially reaching up to USD 131.6 million. Additionally, Henlius will be entitled to royalties based on net sales.
Clinical Development
HLX15, an investigational biosimilar being developed to treat multiple myeloma, successfully completed a Phase I clinical study in mainland China in June of last year. This milestone underscores the potential of HLX15 as a treatment option for patients with multiple myeloma.
Future Outlook
With this licensing deal, Henlius Biotech is poised to expand its global footprint through collaboration with Dr. Reddy’s. The partnership aims to bring a cost-effective treatment option to patients in key markets, leveraging Dr. Reddy’s extensive distribution network and commercial capabilities.-Fineline Info & Tech
